REGIONAL AND INTRAREGIONAL CLUSTERS

NOVUM RESEARCH PARK 1972Huddinge University Hospital Novum Research Foundations Center for Biotechnology Center for Nutrition & Toxicology Center for Structural Biochemistry Center for Oral Biology Founders: Stockholm County Council & Karolinska Institute Purpose: To create a biomedical center of excellence R&D companies in and near Novum. Expanison of research Improvements of infrastructure (communications, hotel, shops) 1989Novum Research Center University of Södertörn Planning for Novum BioCity

NOVUM RESEARCH PARK A.D A qualified environment for front-line research and for the establishment and growth of research-based companies Novum Research Foundations (4 foundations ~ 350 employees) biomedical basic research Departments & Centers of Research (~ 350 employees) Karolinska Institute, Huddinge University Hospital, Södertörn University biomedical & medical technology research Research Companies (20 companies, ~ 450 employees) Novum Business Development Group business counselling, strategic planning information & visitor’s service

NOVUM PRECLINICAL RESEARCH Nuclear receptors Signal transduction Molecular genetics Molecular nutrition Molecular immunology Structural biochemistry

NOVUM CLINICAL RESEARCH Cancer Osteoporosis Metabolic disorders Alzheimer’s disease Cellular therapy Virus infection (Hepatitis) Gene therapy

NEIGHBOURS AND PARTNERS IN NOVUM RESEARCH PARK HUDDINGE UNIVERSITY HOSPITAL THE KAROLINSKA INSTITUTET MEDICAL SCHOOL SÖDERTÖRN UNIVERSITY COLLEGE SERVICE COMPANIES (about 25) _______________________ Appr personer (employees & students) working daily in the park area

BUSINESS COUNSELLING IN NOVUM Patenting Licensing Business law Market analysis Business Planning Financing

NOVUM’S RESEARCH COMPANIES Multinationals AstraZenecaPain Control Research Baxter MedicalRenal Function Research Sumitomo Pharmaceuticals Alzheimer’s disease

Novum’s Research Companies R&D specialists Karo BioReceptorbiology MedivirHIV & Herpes antivirals TripepHIV antivirals LightUp TechnologiesDNA probe technology/diagnostics AvarisGenevector technolog OxypharmaRheumatoid Arthritis

NOVUM’S RESEARCH COMPANIES Service & Technology providers CyberGeneSequencing, genetic diagnostics Nova Snitt AnalysisHistology SciBaseImpedance analysis of skin & mucosa Innomed-Konsult Design of GMP facilities

NOVUM BIOCITY

NOVUM RESEARCH PARK

Nuclear Receptors Large family of receptorsImportant drugs on the market Validated drug targetsBind hormones with high affinity New technology and receptors offer improved treatments and new indications Target gene Nuclear Receptor Hormones or Metabolic Intermediates Protein Changed Cell Function

LXR New Promising Target for Atherosclerosis Upregulates cholesterol pump (ABCA1) Upregulates APO-E in macrophages Upregulates 7- hydroxylase (cholesterol break down)

LXR Concept to Treat Atherosclerosis LXR stimulates synthesis of ABC1 protein Drug compound stimulates LXR activity LXR ABC1-protein + Cell Atherosclerosis Tangier disease; non-functional ABC-1 leads to atherosclerosis Treated blood vessel ABC1 removes harmful cholesterol

Karo Bio – Leader in Nuclear Receptor and Proteomics-Based Drug Discovery

Karo Bio AB Stockholm Karo Bio USA, Inc. Durham, NC Karo Bio, Inc. San Francisco Bayer AG GPC Biotech NovImmune S.A. Serono International Aventis Boehringer Ingelheim BMSMerckAHPAbbott

 Develop pharmaceuticals for major markets  Be a leading company within the field of nuclear receptors and proteomics-based drug discovery  Conduct clinical development and marketing through partners and licensees  Finance operations through partnerships Business Concept

Revenue Model of Karo Bio DrugdiscoveryPre-clinicaldevelopmentClinicaldevelopmentMarket Royalty on sales Targetidentification Up-front payment Research funding R&D milestones

Strategic Position Scientific network Partners KARO BIO Karolinska Insitutet UCSF Duke University University of Bochum Sahlgrenska Hospital University of York … Abbott Laboratories Bristol-Myers Squibb Merck & Co, Inc. Aventis…

Nuclear Receptor Project Portfolio Drug discovery Preclinical Development Phase IPhase IIPhase IIINDA Target and indication validation THR Cardiac arrhythmia /KB ER Merck THR Obesity BMS THR 015/Cardiac arrhythmia/KB THR KB2611/ Skin atrophy /KB THR Glaucoma/KB GR Diabetes Abbott Anti-microbials/KB LXR AHP AR Prostate cancer /KB MR Heart failure /KB GR Inflammation /KB …...C l i n i c a l D e v e l o p m e n t…...

Karo Bio has a diverse nuclear receptor research portfolio Drug discovery Preclinical development Phase IPhase IIPhase III NDA/ Market Disease area Clinical development Oestrogen receptor Type II diabetes Obesity Athero- sclerosis Karo Bio has four profitable nuclear receptor collaborations in potential block-buster areas 80 MUSD + Royalties 56 MUSD + Royalties 40 MUSD + Royalties 100 MUSD + Royalties

Några reflektioner kring ett nytt paradigm för medicinsk och bioteknisk forskning Avståndet mellan laboratoriebänken och patientens säng har minskat betydligt och minskar allt snabbare i takt med den nya molekylärbiologiska forskningens landvinningar Enda sättet att föra över forskningsresultat från lab.bänken till patienten går via patentering och kommersialisering Den nutida laboratorieforskaren har ett etiskt imperativ att börja arbeta i denna riktning (modern tillämpning av den Hippokratiska eden!)

Några reflektioner…… (forts.) Det nya paradigmet för medicinsk/naturvetenskaplig forskning består i en trestegsraket, akademi, SMEs samt stora företag, där de två första stegen bör samlokaliseras under ett tak I detta cluster kommer nya forskningsstrategier och forskningstekniker att växa fram samtidigt som nya utbildningslinjer med kombinationer av bioteknik, medicin, ekonomi, juridik, etik mm kommer att utvecklas Allt detta betyder effektivare forskning, större konkurrenskraft i ett internationellt perspektiv samt bättre ekonomi för Sverige